A Long-Term Safety and Tolerability Study of TV-46000 for Subcutaneous Use in Patients with Schizophrenia: A Phase 3, Randomized, Double-Blinded Clinical Trial.
Saved in:
| Title: | A Long-Term Safety and Tolerability Study of TV-46000 for Subcutaneous Use in Patients with Schizophrenia: A Phase 3, Randomized, Double-Blinded Clinical Trial. |
|---|---|
| Authors: | Kane JM; Department of Psychiatry, The Zucker Hillside Hospital, Northwell Health, 75-59 263rd St, Glen Oaks, NY, 11004, USA.; Department of Psychiatry, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA.; Feinstein Institutes for Medical Research, Institute of Behavioral Science, Manhasset, NY, USA., Eshet R; Innovative Medicines, Global Clinical Development, Teva Pharmaceutical Industries Ltd., Netanya, Israel., Harary E; Innovative Medicines, Global Clinical Development, Teva Pharmaceutical Industries Ltd., Netanya, Israel., Tohami O; Innovative Medicines, Global Clinical Development, Teva Pharmaceutical Industries Ltd., Netanya, Israel., Elgart A; Innovative Medicines, Global Clinical Development, Teva Pharmaceutical Industries Ltd., Netanya, Israel., Knebel H; Global Patient Safety and Pharmacovigilance, Teva Pharmaceutical Industries Ltd. , Netanya, Israel., Sharon N; Innovative Medicines, Global Clinical Development, Teva Pharmaceutical Industries Ltd., Netanya, Israel., Suett M; Global Medical Affairs, Teva UK Limited, Harlow, UK., Franzenburg KR; Global Medical Affairs, Teva Branded Pharmaceutical Products R&D, Inc., West Chester, PA, USA., Davis GL 3rd; Global Clinical Operations, Teva Branded Pharmaceutical Products R&D, Inc., West Chester, PA, USA., Correll CU; Department of Psychiatry, The Zucker Hillside Hospital, Northwell Health, 75-59 263rd St, Glen Oaks, NY, 11004, USA. CCorrell@northwell.edu.; Department of Psychiatry, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA. CCorrell@northwell.edu.; Feinstein Institutes for Medical Research, Institute of Behavioral Science, Manhasset, NY, USA. CCorrell@northwell.edu.; Department of Child and Adolescent Psychiatry, Charité - Universitätsmedizin Berlin, Berlin, Germany. CCorrell@northwell.edu. |
| Source: | CNS drugs [CNS Drugs] 2024 Aug; Vol. 38 (8), pp. 625-636. Date of Electronic Publication: 2024 Jul 02. |
| Publication Type: | Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Adis, Springer International Country of Publication: New Zealand NLM ID: 9431220 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1179-1934 (Electronic) Linking ISSN: 11727047 NLM ISO Abbreviation: CNS Drugs Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| FullText | Links: – Type: pdflink Text: Availability: 1 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 38954317 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: A Long-Term Safety and Tolerability Study of TV-46000 for Subcutaneous Use in Patients with Schizophrenia: A Phase 3, Randomized, Double-Blinded Clinical Trial. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Kane+JM%22">Kane JM</searchLink>; Department of Psychiatry, The Zucker Hillside Hospital, Northwell Health, 75-59 263rd St, Glen Oaks, NY, 11004, USA.; Department of Psychiatry, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA.; Feinstein Institutes for Medical Research, Institute of Behavioral Science, Manhasset, NY, USA.<br /><searchLink fieldCode="AU" term="%22Eshet+R%22">Eshet R</searchLink>; Innovative Medicines, Global Clinical Development, Teva Pharmaceutical Industries Ltd., Netanya, Israel.<br /><searchLink fieldCode="AU" term="%22Harary+E%22">Harary E</searchLink>; Innovative Medicines, Global Clinical Development, Teva Pharmaceutical Industries Ltd., Netanya, Israel.<br /><searchLink fieldCode="AU" term="%22Tohami+O%22">Tohami O</searchLink>; Innovative Medicines, Global Clinical Development, Teva Pharmaceutical Industries Ltd., Netanya, Israel.<br /><searchLink fieldCode="AU" term="%22Elgart+A%22">Elgart A</searchLink>; Innovative Medicines, Global Clinical Development, Teva Pharmaceutical Industries Ltd., Netanya, Israel.<br /><searchLink fieldCode="AU" term="%22Knebel+H%22">Knebel H</searchLink>; Global Patient Safety and Pharmacovigilance, Teva Pharmaceutical Industries Ltd. , Netanya, Israel.<br /><searchLink fieldCode="AU" term="%22Sharon+N%22">Sharon N</searchLink>; Innovative Medicines, Global Clinical Development, Teva Pharmaceutical Industries Ltd., Netanya, Israel.<br /><searchLink fieldCode="AU" term="%22Suett+M%22">Suett M</searchLink>; Global Medical Affairs, Teva UK Limited, Harlow, UK.<br /><searchLink fieldCode="AU" term="%22Franzenburg+KR%22">Franzenburg KR</searchLink>; Global Medical Affairs, Teva Branded Pharmaceutical Products R&D, Inc., West Chester, PA, USA.<br /><searchLink fieldCode="AU" term="%22Davis+GL+3rd%22">Davis GL 3rd</searchLink>; Global Clinical Operations, Teva Branded Pharmaceutical Products R&D, Inc., West Chester, PA, USA.<br /><searchLink fieldCode="AU" term="%22Correll+CU%22">Correll CU</searchLink>; Department of Psychiatry, The Zucker Hillside Hospital, Northwell Health, 75-59 263rd St, Glen Oaks, NY, 11004, USA. CCorrell@northwell.edu.; Department of Psychiatry, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA. CCorrell@northwell.edu.; Feinstein Institutes for Medical Research, Institute of Behavioral Science, Manhasset, NY, USA. CCorrell@northwell.edu.; Department of Child and Adolescent Psychiatry, Charité - Universitätsmedizin Berlin, Berlin, Germany. CCorrell@northwell.edu. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%229431220%22">CNS drugs</searchLink> [CNS Drugs] 2024 Aug; Vol. 38 (8), pp. 625-636. <i>Date of Electronic Publication: </i>2024 Jul 02. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study; Research Support, Non-U.S. Gov't – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Adis%2C+Springer+International%22">Adis, Springer International </searchLink><i>Country of Publication: </i>New Zealand <i>NLM ID: </i>9431220 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1179-1934 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2211727047%22">11727047 </searchLink><i>NLM ISO Abbreviation: </i>CNS Drugs <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=38954317 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1007/s40263-024-01102-2 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 625 Titles: – TitleFull: A Long-Term Safety and Tolerability Study of TV-46000 for Subcutaneous Use in Patients with Schizophrenia: A Phase 3, Randomized, Double-Blinded Clinical Trial. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Kane JM – PersonEntity: Name: NameFull: Eshet R – PersonEntity: Name: NameFull: Harary E – PersonEntity: Name: NameFull: Tohami O – PersonEntity: Name: NameFull: Elgart A – PersonEntity: Name: NameFull: Knebel H – PersonEntity: Name: NameFull: Sharon N – PersonEntity: Name: NameFull: Suett M – PersonEntity: Name: NameFull: Franzenburg KR – PersonEntity: Name: NameFull: Davis GL 3rd – PersonEntity: Name: NameFull: Correll CU IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 08 Text: 2024 Aug Type: published Y: 2024 Identifiers: – Type: issn-electronic Value: 1179-1934 Numbering: – Type: volume Value: 38 – Type: issue Value: 8 Titles: – TitleFull: CNS drugs Type: main |
| ResultId | 1 |
